News - 25 Mar `22Vitiligo news from AAD annual meeting

New

This year’s American Academy of Dermatology (AAD) Annual Meeting is already in full swing in Boston. 

Nicolle Maquignon, VIPOC General secretary, reports from the GVF session: "Amit G Pandya, President, welcomed the participants. His speech was, as usual, very warming and showed how much he cares for the patients: find new resources, spread good information, give emotional as well as educational support to the individuals with vitiligo, educate the doctors, empower people to live well with vitiligo. <...> Doctors and scientists focused on the role of the patients and the groups support, in their studies, and are more and more aware about the burden, showing and talking about “humanity” in their relations with the patients."

All eyes will be on Incyte tomorrow as it reveals details on two Phase III trials studying its JAK1/JAK2 inhibitor ruxolitinib cream for vitiligo. To recap, the FDA extended its review of ruxolitinib in vitiligo for three months from 18 April to 18 July. Ruxolitinib is currently available for atopic dermatitis under the brand name Opzelura, and a potential expansion to vitiligo is key for Incyte's plans to diversify its revenue base. A similar delay happened when the company sought FDA approval for the cream in atopic dermatitis, but it eventually received FDA approval in the mild-to-moderate setting in patients 12 years old and over.

Vitiligo_AAD2022_John_Harris

Photo (c) Nicolle Maquignon: Prof. John Harris, MD, Department of Dermatology at the University of Massachusetts Medical School presents “The vitiligo pathogenesis and updated emerging treatments” 

 

      FAQOther Questions

      • I have a new job - should I tell colleagues about my vitiligo?

        If you are starting a new job and you are concerned about stares and questions about your skin, try a proactive approach. When the time is right and you are feeling comfortable,...

      • Can chemicals cause vitiligo?

        It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...

      • What is vitiligo?

         Vitiligo (pronounced vit-ill-EYE-go) is a generally unpredictable skin disease that causes a gradual loss of skin color and overlying hair on different parts of the body. Cont...